Loading...
XSHG
600420
Market cap1.96bUSD
Dec 05, Last price  
10.33CNY
1D
0.19%
1Q
-8.83%
Jan 2017
-37.62%
IPO
355.07%
Name

Shanghai Shyndec Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600420 chart
P/E
12.79
P/S
1.27
EPS
0.81
Div Yield, %
1.94%
Shrs. gr., 5y
3.10%
Rev. gr., 5y
-2.16%
Revenues
10.94b
-8.33%
502,746,161545,870,580624,322,933687,231,9331,164,233,7281,422,963,6451,702,623,2752,006,892,2342,349,747,9942,748,835,6682,682,244,6909,125,774,7738,517,753,72611,320,781,39312,199,106,72512,556,281,59513,944,948,27012,959,320,53311,931,810,34310,937,525,114
Net income
1.08b
+56.62%
58,686,12150,497,72894,029,95853,914,13789,052,252108,111,439120,032,511115,944,722132,787,532189,991,042221,052,732476,933,718515,802,593705,521,698928,467,067900,046,866821,145,853867,484,979691,880,4951,083,622,881
CFO
2.26b
+31.13%
57,898,13273,595,32782,308,03658,044,42597,434,742115,105,986136,123,080193,411,432207,496,007258,514,766226,646,450838,576,8382,314,541,6561,669,140,5751,270,137,2121,560,179,0111,679,662,3932,855,633,1051,720,373,7882,255,980,695
Dividend
Sep 20, 20240.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism, and endocrine areas. The company was founded in 1996 and is based in Shanghai, China.
IPO date
Jun 16, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT